Mymetics HIV Vaccine Shows Strong Preliminary Phase I Data

I found this article interesting, especially with the recent marking of World AIDS Day on December 1, due to its incredible relevance to many people around the world today. The technology in the proposed HIV-1 vaccine is not only revolutionizing treatment of HIV patients, but vaccines in general. Instead of trying to improve upon technology that is already present by focusing on a vaccine that produces more/better blood serum antibodies, Mymetics is developing a vaccine that will produce serum as well as mucosal antibodies. This approach has the potential to be extremely effective for prevention of transmission of HIV, seeing as mucosal antibodies provide a front line of defense as they prevent the attachment of HIV-1 to epithelial cells along mucosal surfaces, such as the genital tract.

http://www.mymetics.com/investor/press-releases/103-mymeticshivvaccinenovember302100-showsstrongpreliminaryphaseidata